Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 1047-1057

  Temmink, Olaf H ^a   Bijnsdorp, Irene V ^a   Prins, Henk Jan ^a   Losekoot, Nienke ^a   Adema, Auke D ^a   Smid, Kees ^a   Honeywell, Richard J ^a   Ylstra, Bauke ^a   Eijk, Paul P ^a   Fukushima, Masakazu ^b   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; MESSENGER RNA; SECRETORY PHOSPHOLIPASE A2; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TRIFLURIDINE;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CHROMOSOME 17; CHROMOSOME 19; COLON CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EQUILIBRATIVE NUCLEOSIDE TRANSPORT PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPID METABOLISM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOLIPASES A2, SECRETORY; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; TRIFLURIDINE; UP-REGULATION;

EID: 77950804513     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0932     Document Type: Article

References (50)

1. Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci 2007;98: 779-789
2. Eckstein JW, Foster PG, Finer-Moore J, Wataya Y, Santi DV. Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)- 2′-deoxyuridine 5′-monophosphate. Biochemistry 1994; 33:15086-15094
3. Santi DV, Sakai TT. Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2′-deoxyuridylic acid. Biochemistry 1971;10:3598-3607
4. van Triest B, Peters GJ. Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999;57:179-194
5. Webley SD, Welsh SJ, Jackman AL, Aherne GW. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. Br J Cancer 2001;85: 446-452
6. Aherne GW, Hardcastle A, Raynaud F, Jackman AL. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol 1996;51:1293-1301
7. Peters GJ, van Triest B, Backus HH, Kuiper CM, van der Wilt CL, Pinedo HM. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer 2000;36: 916-924
8. Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205.
9. Aschele C, Lonardi S, Monfardini S. Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidinebased chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002;28:27-47.
10. Yamachika T, Nakanishi H, Inada K, et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998;82:70-77
11. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995;49:1419-1426
12. Drori S, Jansen G, Mauritz R, Peters GJ, Assaraf YG. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem 2000;275:30855-30863
13. Peters GJ, Jansen G. Resistance to antimetabolites. In: Schilsky RL, Milano GA, Ratain MJ, editors. Principles of Antineoplastic Drug Development and Pharmacology. New York: Marcel Dekker Inc; 1996, p. 543-585
14. Pastor-Anglada M, Felipe A, Casado FJ. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends Pharmacol Sci 1998;19:424-30.
15. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-1302
16. Johnston PG, Drake JC, Trepel J, Allegra CJ. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992;52:4306-4312
17. Drake JC, Allegra CJ, Moran RG, Johnston PG. Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Biochem Pharmacol 1996;51:1349-1355
18. Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 2000;17:277-283
19. Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 2004;13:545-549
20. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991;27:897-900.
21. Bijnsdorp IV, Kruyt FA, Gokoel S, Fukushima M, Peters GJ. Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. Cancer Sci 2008;99:2302-2308
22. van der Wilt CL, Backus HH, Smid K, et al. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 2001;61: 3675-3681
23. Ceresa C, Giovannetti E, Voortman J, et al. Bortezomib induces schedule-dependent modulation of gemcitabine pharmaxcokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Mol Cancer Ther 2009;8: 1026-1036
24. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, editors. Bioinformatics Methods and protocols: Methods in Molecular Biology. Totowa: Humana Press; 2000, p. 365-386
25. Mackey JR, Galmarini CM, Graham KA, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. Blood 2005; 105:767-774
26. Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003;101:1270-1276
27. Carrascal M, Schneider K, Calaf RE, van Leeuwen S, Canosa D, Gelpi E, et al. Quantitative electrospray LC-MS and LC-MS/MS in biomedicine. J Pharm Biomed Anal 1998;17:1129-1138
28. van den IIssel P, Tijssen M, Chin SF, et al. Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res 2005; 33:e192.
29. Bergman AM, Eijk PP, Ruiz van Haperen VW, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005;65:9510-9516
30. Buffart TE, Israeli D, Tijssen M, et al. Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. Genes Chromosomes Cancer 2008;47: 994-1004.
31. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991;266: 9032-9038
32. Grade M, Becker H, Liersch T, Ried T, Ghadimi BM. Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact. Cell Oncol 2006;28:71-84.
33. Postma C, Koopman M, Buffart TE, et al. DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol 2009;20: 1048-1056
34. De Bruin M, van Capel T, van der Born K, et al. Role of plateletderived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 2003;88:957-964
35. Morioka Y, Ikeda M, Saiga A, et al. Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis. FEBS Lett 2000; 487:262-266
36. Fijneman RJ, Cormier RT. The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. Front Biosci 2008;13: 4144-4174
37. Leung SY, Chen X, Chu KM, et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A 2002;99:16203-16208
38. Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I. Regulatory functions of phospholipase A2. Crit Rev Immunol 1997;17: 225-283
39. Selzner M, Bielawska A, Morse MA, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 2001; 61:1233-1240
40. Schmelz EM. Sphingolipids in the chemoprevention of colon cancer. Front Biosci 2004;9:2632-2639
41. Zhao S, Du XY, Chai MQ, Chen JS, Zhou YC, Song JG. Secretory phospholipase A(2) induces apoptosis via a mechanism involving ceramide generation. Biochim Biophys Acta 2002;1581: 75-88.
42. Tillman DM, Petak I, Houghton JA. Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 1999;5:425-430
43. Ciccolini J, Fina F, Bezulier K, et al. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol Cancer Ther 2002;1:923-927
44. Backus HH, Dukers DF, van Groeningen CJ, et al. 5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann Oncol 2001;12: 209-216
45. Backus HH, Wouters D, Ferreira CG, et al. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer 2003;39:1310-1317
46. Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M, Kruyt FA. Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer 2000 Oct 8 [Epub ahead of print].
47. Andresen TL, Jensen SS, Madsen R, Jorgensen K. Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase a(2) in tumor tissue. J Med Chem 2005;48:7305-7314
48. Jensen SS, Andresen TL, Davidsen J, et al. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther 2004;3:1451-1458
49. Garcia-Garcia HM, Serruys PW. Phospholipase A2 inhibitors. Curr Opin Lipidol 2009;20:327-332
50. Temmink OH, de Bruin M, Comijn EM, Fukushima M, Peters GJ. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. Anticancer Drugs 2005;16:285-292